Agonists of the GLP‐1 receptor (GLP‐1R), including exenatide (Byetta®) and liraglutide (Victoza®) have been approved for the treatment of T2D and these drugs effectively reduce blood glucose, body weight, and systolic blood pressure. Here, GLP1R is linked to type 2 diabetes mellitus.